Eledon Pharmaceuticals
ELDN
121 hedge funds and large institutions have $131M invested in Eledon Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 35 increasing their positions, 20 reducing their positions, and 15 closing their positions.
1,608% more call options, than puts
Call options by funds: $649K | Put options by funds: $38K
180% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 15
97% more capital invested
Capital invested by funds: $66.7M → $131M (+$64.5M)
75% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 20
27% more funds holding
Funds holding: 95 → 121 (+26)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17.48% less ownership
Funds ownership: 73.67% → 56.19% (-17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.91M |
| 2 |
BlackRock
New York
|
+$1.78M |
| 3 |
State Street
Boston,
Massachusetts
|
+$897K |
| 4 |
CCM
Catalio Capital Management
New York
|
+$895K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$872K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.02M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
-$1.2M |
| 4 |
ZP
Zimmer Partners
New York
|
-$1.2M |
| 5 |
Jane Street
New York
|
-$1.15M |
ELDN Hedge Fund Activity: Q1 2026 in Review
121 institutional investors reported a position in Eledon Pharmaceuticals (ELDN) for Q1 2026, worth a combined $131M — up 97% from $66.7M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ELDN positions and 15 closed out — a net gain of 27 holders — while 35 added to existing stakes and 20 trimmed.
The largest buyer was Bank of America, adding an estimated $1.91M. The largest seller was Stonepine Capital Management, cutting an estimated $2.02M.
- 121 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q1 2026, up from 95 in Q4 2025.
- Funds reported $131M of Eledon Pharmaceuticals stock for Q1 2026, up 97% quarter-over-quarter.
- 42 funds opened new Eledon Pharmaceuticals positions in Q1 2026 and 15 closed out, a net change of +27 holders.
- The largest Eledon Pharmaceuticals buyer in Q1 2026 was Bank of America, an estimated $1.91M added.
- The largest Eledon Pharmaceuticals seller in Q1 2026 was Stonepine Capital Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q1 2026.